Neuroone Medical Technologies (NMTC) Q1 2025 earnings summary

Executive summary

• Achieved record total revenue of $6.3 million in Q1 FY2025, including $3.3 million product revenue and a $3.0 million one-time license payment from Zimmer Biomet, reversing a net loss of $3.3 million in Q1 FY2024 to net income of $1.8 million ($0.06 per share).

• Expanded exclusive distribution agreement with Zimmer Biomet for the OneRF Ablation System, with $3.0 million upfront and potential milestone payments.

• OneRF ablation system continues to show strong clinical outcomes, with most patients seizure-free post-procedure and positive adoption in epilepsy centers.

• Regained compliance with Nasdaq listing standards as of February 2025.

• Ended the quarter with $1.1 million in cash and cash equivalents, with substantial doubt about the ability to continue as a going concern without additional funding.

Financial highlights

• Product revenue reached $3.3 million, up 235% year-over-year from $1 million in Q1 FY2024; license revenue of $3 million recognized in Q1 FY2025 from Zimmer Biomet.

• Product gross margin improved to 58.9% from 27.2% year-over-year.

• Net income of $1.8 million ($0.06 per share) versus a net loss of $3.3 million ($0.14 loss per share) in Q1 FY2024.

• Operating expenses decreased 12% year-over-year to $3.2 million.

• Cash provided by operating activities was $0.2 million, compared to $3.8 million used in the prior year period.

Outlook and guidance

• FY2025 product revenue expected between $8–$10 million, up 132%–190% from FY2024, with product gross margin guidance of 47%–51%.

• Sequential product revenue decline expected in Q2 FY2025 due to initial stocking, with ramp-up later in the year.

• Guidance excludes license payments from Zimmer Biomet.

• Management expects continued operating and net losses until higher commercial sales are achieved; additional funding required to support operations beyond April 2025.

• Anticipates increased expenses for product development, commercialization, and regulatory activities.